每经AI快讯，金花股份（SH 600080，收盘价：8.62元）11月24日晚间发布公告称，2025年11月24日， 金花企业（集团）股份有限公司控股股东、实际控制人邢博越及其一致行动人杜玲、杨蓓签订了《股权 转让协议书》，杜玲、杨蓓拟通过协议转让的方式分别将各自持有的公司约1097万股（占公司总股本的 2.94%）、约1055万股（占公司总股本的2.83%），合计约2152万股（占公司总股本的5.77%）转让予邢 博越。邢博越承诺在上述股权转让过户完成之日起12个月内不减持所持有的公司股份。本次协议转让系 公司控股股东、实际控制人邢博越及其一致行动人之间内部转让，其合计持股比例、数量和表决权未发 生变化。不涉及向市场减持，不触及要约收购，不会导致公司控股股东及实际控制人发生变化。 截至发稿，金花股份市值为32亿元。 每经头条（nbdtoutiao）——大鹏工业战略配售"肥"了自家人！认购价9元，上市首日涨到118元，实控 人和亲哥哥凭配售一天浮盈2492万元 （记者 曾健辉） 2024年1至12月份，金花股份的营业收入构成为：医药工业占比99.89%，医药商业占比0.14%，酒店业 占比0.03%，内部抵销 ...

Core Points - The announcement reveals that the controlling shareholder and actual controller of Jinhua Co., Ltd. (stock code: 600080), Xing Boyue, along with his concerted actors Du Ling and Yang Bei, have signed a share transfer agreement [1] - Du Ling and Yang Bei plan to transfer a total of 21.52 million shares, which accounts for 5.77% of the company's total share capital, to Xing Boyue [1] - The share transfer is an internal transfer among the controlling shareholder and his concerted actors, and there will be no change in the total shareholding ratio, quantity, or voting rights [1] Summary by Sections - **Share Transfer Details** - Du Ling will transfer 10.97 million shares (2.94% of total share capital) - Yang Bei will transfer 10.55 million shares (2.83% of total share capital) - The total shares transferred amount to 21.52 million [1] - **Commitment on Shareholding** - Xing Boyue has committed not to reduce his shareholding within 12 months after the completion of the share transfer [1]

金花企业（集团）股份有限公司 简式权益变动报告书 金花企业（集团）股份有限公司 简式权益变动报告书 上市公司名称：金花企业（集团）股份有限公司 股票上市地点：上海证券交易所 股票简称：金花股份 股票代码：600080 信息披露义务人（一致行动人）一：杜玲 金花企业（集团）股份有限公司 简式权益变动报告书 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司收购管理办法》（以下简称"《收购管理办法》"）、《公开发行证 券公司信息披露内容与格式准则第 15 号—权益变动报告书》（以下简称"准则 15 号"）及相关的法律、法规编写本报告书。 信息披露义务人（一致行动人）二：杨蓓 住所：西安市莲湖区白露湾 权益变动性质：股份减少 权益变动性质：股份在一致行动人之间转让，合计持股不变 签署日期：二〇二五年十一月 1 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 住所：西安市雁塔区太白南路三号 权益变动性质：股份减少 三、依据《证券法》、《收购管理办法》的规定，本报告书已全面披露信息 披 ...

证券代码：600080 证券简称：金花股份 公告编号：2025-046 金花企业（集团）股份有限公司 关于公司控股股东、实际控制人与一致行动人协议转 让股份的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2025 年 11 月 24 日，金花企业（集团）股份有限公司（以下简称"公司"） 控股股东、实际控制人邢博越及其一致行动人杜玲、杨蓓签订了《股权转让协议 书》，杜玲、杨蓓拟通过协议转让的方式分别将各自持有的公司 10,974,247 股（占 公司总股本的 2.94%）、10,545,559 股（占公司总股本的 2.83%），合计 21,519,806 股（占公司总股本的 5.77%）转让予邢博越。邢博越承诺在上述股权转让过户完 成之日起 12 个月内不减持所持有的公司股份。 本次协议转让系公司控股股东、实际控制人邢博越及其一致行动人之间 内部转让，其合计持股比例、数量和表决权未发生变化。不涉及向市场减持，不 触及要约收购，不会导致公司控股股东及实际控制人发生变化。本次协议转让前， 邢博越持有 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.21% on November 20, with Kanghui Co., Ltd. leading the drop [1] - The Shanghai Composite Index closed at 3931.05, down 0.4%, while the Shenzhen Component Index closed at 12980.82, down 0.76% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - *ST Changyao: Closed at 2.83, up 19.92% with a trading volume of 763,900 shares and a turnover of 197 million yuan [1] - Jinhua Co., Ltd.: Closed at 69.8, up 7.15% with a trading volume of 577,400 shares and a turnover of 505 million yuan [1] - Tailong Pharmaceutical: Closed at 7.44, up 3.33% with a trading volume of 344,200 shares and a turnover of 25.2 million yuan [1] - Conversely, Kanghui Co., Ltd. saw a decline of 3.72%, closing at 22.26 with a trading volume of 27,400 shares and a turnover of 61.69 million yuan [2] Capital Flow - The Chinese medicine sector experienced a net outflow of 143 million yuan from institutional investors, while retail investors saw a net inflow of 133 million yuan [2] - Key stocks with significant capital flow included: - Jinhua Co., Ltd.: Institutional net inflow of 99.64 million yuan, retail net outflow of 79.86 million yuan [3] - Zhongsheng Pharmaceutical: Institutional net inflow of 92.18 million yuan, retail net outflow of 51.91 million yuan [3] - Tailong Pharmaceutical: Institutional net inflow of 25.82 million yuan, retail net outflow of 31.90 million yuan [3]

Market Overview - The Chinese medicine sector rose by 0.39% on November 12, with Zhongsheng Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] Top Performers - Zhongsheng Pharmaceutical (002317) closed at 23.38, up 10.02% with a trading volume of 1.3442 million shares [1] - Panlong Pharmaceutical (002864) closed at 35.64, up 10.00% with a trading volume of 162,700 shares [1] - Te Yi Pharmaceutical (002728) closed at 13.41, up 5.09% with a trading volume of 1.6884 million shares [1] - Other notable gainers include Jiu Zhi Tang (000989) up 4.99% and Jin Hua Co. (600080) up 4.93% [1] Underperformers - Yiling Pharmaceutical (002603) closed at 20.01, down 2.25% with a trading volume of 668,600 shares [2] - Weikang Pharmaceutical (300878) closed at 28.72, down 1.98% with a trading volume of 99,900 shares [2] - Kangmei Pharmaceutical (600518) closed at 2.09, down 1.42% with a trading volume of 2.9625 million shares [2] Capital Flow - The Chinese medicine sector saw a net inflow of 196 million yuan from institutional investors, while retail investors contributed a net inflow of 80.93 million yuan [2] - Speculative funds experienced a net outflow of 277 million yuan [2] Individual Stock Capital Flow - Zhongsheng Pharmaceutical had a net inflow of 4.03 billion yuan from institutional investors, but a net outflow of 2.13 billion yuan from speculative funds [3] - Tongrentang (600085) saw a net inflow of 1.22 billion yuan from institutional investors, with a net outflow of 508.17 million yuan from speculative funds [3] - Other stocks like Pian Zai Huang (600436) and Dong E E Jiao (000423) also experienced significant net inflows from institutional investors [3]

Group 1 - The flu concept is experiencing renewed activity, leading to significant stock movements in related companies [1] - Te Yi Pharmaceutical has achieved two consecutive trading limits, indicating strong market interest [1] - Bo Hui Innovation has reached a 20% daily limit increase, reflecting positive investor sentiment [1] Group 2 - Panlong Pharmaceutical has also hit the daily limit, showcasing its strong performance in the market [1] - Other companies such as Zhongsheng Pharmaceutical, Ha Sanlian, and Jinhua Co. have seen their stocks rise in response to the flu concept's resurgence [1]

Core Viewpoint - Jinhua Co., Ltd. is a well-known pharmaceutical company in China, established in 1996 and listed in 1997, with a strong focus on drug research, production, and sales, but its revenue and net profit rankings are significantly lower than industry leaders [1][2]. Group 1: Business Performance - For Q3 2025, Jinhua's revenue was 384 million yuan, ranking 59th out of 69 in the industry, significantly lower than the top company, Baiyunshan, with 61.61 billion yuan, and the industry average of 375.5 million yuan [2]. - The net profit for the same period was 34.24 million yuan, ranking 47th out of 69, again far below the leading company, Yunnan Baiyao, which reported 4.789 billion yuan, and the industry average of 447 million yuan [2]. Group 2: Financial Ratios - Jinhua's debt-to-asset ratio was 19.09% in Q3 2025, up from 18.29% the previous year, which is significantly lower than the industry average of 32.81%, indicating a lower debt burden [3]. - The gross profit margin for Q3 2025 was 76.55%, slightly down from 77.98% year-on-year, but still above the industry average of 52.44%, reflecting strong product profitability [3]. Group 3: Executive Compensation - The chairman, Xing Yajiang, received a salary of 1.1203 million yuan in 2024, an increase of 576,000 yuan from 2023 [4]. - The general manager, Han Zhuojun, earned 809,800 yuan in 2024, up by 113,200 yuan from the previous year [4]. Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 2.22% to 20,100, while the average number of circulating A-shares held per account increased by 2.27% to 18,600 [5].

Core Viewpoint - Jinhua Co., Ltd. (600080.SH) reported its Q3 2025 results, indicating a decrease in institutional ownership compared to the previous quarter [1] Institutional Ownership - As of October 29, 2025, two institutional investors disclosed holdings in Jinhua Co., Ltd., totaling 20.4263 million shares, which represents 5.47% of the total share capital [1] - The institutional ownership ratio decreased by 0.80 percentage points compared to the previous quarter [1] Public Fund Holdings - In this reporting period, 12 public funds were not disclosed compared to the previous quarter, including notable funds such as: - China Merchants CSI Consumer Leaders Index Enhanced A - Huaxia Dingrong Bond A - Bodao Consumption Smart Navigation A - Guolian SSE Sci-Tech Innovation Board Comprehensive Index Enhanced A - Huiquan Qiyuan Future Mixed Initiation A [1]

Summary of Key Points Core Viewpoint - On October 29, Hangzhou Oxygen Plant Co., Ltd. disclosed an increase in shareholding, while 11 A-share listed companies announced plans for share reductions [1][2]. Group 1: Shareholding Increases - Hangzhou Oxygen Plant received a stake increase from CITIC Financial Assets, raising its holding to 5% [2]. Group 2: Shareholding Reductions - Greenfield Machinery: Shareholder Shao Yutian plans to reduce holdings by no more than 3% [2]. - Jianghua Micro: Shareholder Yin Fuhua intends to reduce holdings by no more than 3% [2]. - Jiuzhou Group: Shareholders plan to collectively reduce holdings by no more than 1.88% [2]. - Guorui Technology: Shareholder Gong Ruiliang plans to reduce holdings by no more than 3% [2]. - Kairun Co., Ltd.: Shareholder Li Zhongren plans to reduce holdings by no more than 1.70% [2]. - Yingjixin: Shareholder plans to transfer 2.9% of company shares through inquiry [2]. - Mindong Electric: Shareholder Provincial Investment Group intends to reduce holdings by no more than 1% [2]. - WuXi AppTec: Shareholders controlled by the actual controller plan to reduce holdings by no more than 2% [2]. - Zhongwei Company: A dedicated repurchase account plans to reduce holdings by no more than 0.33% [2]. - Jinhua Co., Ltd.: Plans to reduce no more than 746.54 million shares that have been repurchased [2]. - Hechuan Technology: Bosch China intends to reduce holdings by no more than 3% [2].